Volume 1, Number 2, December 2000

Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
Marc A Pfeffer

A number of other large-scale studies on valsartan and related ARBs are expected to provide definitive results to answer open questions about the role of ARBs in the treatment of cardiovascular disease. The design feature of VALIANT, as a large modern trial testing both the direct comparison as well as the combination of an ACE inhibitor and ARB, ensures that its results will contribute substantially to our understanding of the benefits to post-MI patients provided by different RAAS inhibitor treatments.

JRAAS 2000;1:41-43.

View full PDF article (open in new window)
Email this article

Right click on this DOI link and copy link to cite this article (What is a DOI link?)